Portal de Periódicos da CAPES

A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection

2011; Oxford University Press; Volume: 203; Issue: 4 Linguagem: Inglês

10.1093/infdis/jiq077

1537-6613

Felipe García, Núria Climent, Lambert Assoumou, Cristina Gil, Núria Gonzàlez, José Alcamı́, Agathe León, Joan Romeu, Judith Dalmau, Javier Martínez‐Picado, Jeff Lifson, Brigitte Autran, Dominique Costagliola, Bonaventura Clotet, Josep M. Gatell, Montserrat Plana, Teresa Gallart,

vaccines and immunoinformatics approaches

A double-blinded, controlled study of vaccination of untreated patients with chronic human immunodeficiency virus type 1 (HIV-1) infection with 3 doses of autologous monocyte-derived dendritic cells (MD-DCs) pulsed with heat inactivated autologous HIV-1 was performed. Therapeutic vaccinations were feasible, safe, and well tolerated. At week 24 after first vaccination (primary end point), a modest significant decrease in plasma viral load was observed in vaccine recipients, compared with control subjects (P = .03). In addition, the change in plasma viral load after vaccination tended to be inversely associated with the increase in HIV-specific T cell responses in vaccinated patients but tended to be directly correlated with HIV-specific T cell responses in control subjects.